|Bid||0.00 x 800|
|Ask||0.00 x 1400|
|Day's Range||10.97 - 11.75|
|52 Week Range||10.45 - 20.87|
|Beta (3Y Monthly)||3.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Bothell, Washington-based company said it had a loss of 91 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.
Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.
Biotech plays are numerous, and Morgan Stanley has a few recommendations to pare and prop a pharma portfolio. The Ratings Analyst Jeffrey Hung initiated coverage of: Alder Biopharmaceuticals Inc (NASDAQ: ...
Until recently, there was no specific treatment for migraine, although symptom-alleviating options such as beta blockers, antidepressants and even Botox were invariably used by affected individuals. Aimovig, a preventative treatment option for migraines, belongs to a class of drugs called calcitonin gene-related peptide — or CGRP — inhibitors and antagonists.
On a per-share basis, the Bothell, Washington-based company said it had a loss of $1.04. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ) is set to release its second-quarter earnings report after the bell Tuesday, and Stifel reviewed the stock ahead of the print. The Analysts Stifel analyst ...
Short interest is high for ALDR with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ALDR. The net inflows of $2.00 billion over the last one-month into ETFs that hold ALDR are not among the highest of the last year and have been slowing.
Investors in Alder Biopharmaceuticals (ALDR) need to pay close attention to the stock based on moves in the options market lately.
Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. Over the last month, growth of ETFs holding ALDR is favorable, with net inflows of $5.46 billion.